Elucid

United States
Panora, Iowa, United States, 02111

Company profile

Elucid company profile

Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Business identity

Contact email
[email protected]
Phone number
617-329-9487
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Postal code
02111
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
10
Total equity funding
$158.5M
Last funding
Series D / $36.5M / 2025-10-22
Last equity funding
Series D / $36.5M
Investors
15
Lead investors
4
Founders
1
Articles
58

Founders and investors

Founders

Andrew J. Buckler

Lead investors

Elevage Medical TechnologiesGlobal Health Impact FundMedTex VenturesNational Science Foundation

Investors

Aphelion CapitalBlueStone Venture PartnersElevage Medical TechnologiesIAG Capital PartnersNational Science Foundation